Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Chronic obstructive pulmonary disease (COPD) is a progressive disorder of the lung parenchyma
and airways, which is the third-leading cause of death in the USA. Current therapies for COPD
are only partially effective and may also have side effects. Although increasing evidence
indicates that quercetin supplementation may be beneficial in treating COPD, key
methodological issues have not been resolved. The overall objective of this study is to
determine the dosage of quercetin supplementation, bioavailability of quercetin, safety,
dose-response relationship and appropriate biomarkers which reflect clinical outcomes in
patients with COPD that is necessary for conducting large clinical trials in this patient
population.
Phase:
Phase 1
Details
Lead Sponsor:
University of Michigan
Collaborators:
National Center for Complementary and Integrative Health (NCCIH) National Institutes of Health (NIH) Quercegen Pharmaceuticals